Bristol-Myers Squibb Co.'s prospects in small cell lung cancer (SCLC) now look doubtful after the US group reported disappointing Phase III data from CheckMate-451 in which Opdivo (nivolumab) combined with Yervoy (ipilimumab) missed the primary endpoint of overall survival, analysts say.
The miss comes shortly after BMS's Phase III Checkmate-331 in relapsed small cell lung cancer using Opdivo failed to meet...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?